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ABSTRACT 
Background and objective: Pregnant women are more susceptible to vaginal colonization and yeast 
infection. The role of Candida colonization in the occurrence of preterm birth is well established. Knowing 
local epidemiology and identifying risk factors for preterm birth are important for prevention and 
management strategies. The purpose of the study was to determine the prevalence of Candida species in 
vaginal swabs for pregnant women and determine associated risk factors of vulvovaginal candidiasis (VVC). 
Methods:   Pregnant women attending routine antenatal visits in Al-Olify –family Center in Sana'a city  
were enrolled into a cross-sectional study carried out from June  2018  to March 2019. The laboratory works 
were carried out in the National Center of Public Laboratories (NCPHL).  Vaginal swabs samples were taken 
from participants after obtaining oral consent. The swabs were inoculated into Sabouraud's glucose agar 
supplemented with chloramphenicol and incubated at 37 °C for 24 to 48 hours under aerobic conditions in 
order to perform fungal culture. The identification of the Candida species was done by culture on 
HiCrome Candida Differential Agar at 35 °C for 48 h for production of species-specific colors. Data of 
demographic, clinical and risk factors were collected in a pre-designed questionnaire. 
Results: A total of 190 pregnant women are included. The prevalence of VVC was 51.6%. Candida albicans 
accounted for 39.5% and non-Candida albicans accounted for 12.1% of isolates, mainly C. glabrata (4.7%), 
C. lipolytica (3.2%), and C. famata (2.1%). When VVC risk factors were considered, there were significant 
risk factors with the age group 20-24 years (61%, OR = 1.8), first trimester of pregnancy (61.1%, OR = 1.7), 
Multipara of  parity (61.8%, OR = 19), low socioeconomic level (60.1%, OR = 2.4), and illiteracy (68%, OR 
= 2.2). When clinical symptoms were considered, only 86.2% of affected females had clinical signs of VVC. 
Conclusions: There is a high rate of VVC among pregnant women in Yemen, and this highlights the need 
for health authorities to develop strategies for diagnosing VVC, including vaginal swabs for candidiasis as a 
routine procedure for all pregnant women. This study also revealed a steady increase in time with a non-
C. albicans species  prevalence rate. VVC syndrome management guidelines in Yemen should be revised to 
include a special protocol for pregnant women. 
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INTRODUCTION  
   VVC is caused by overgrowth of yeasts, especially Candida albicans, which is an essential part of vaginal 
flora
1
. VVC symptoms include vaginal discharge, pain, itching and swelling of vulvar. In addition, vulgar 
erythematosus and edema with obstruction are common results. Typical vaginal secretions in VVC are 
described as cottage cheese-like in character
2
. It is possible that 75.0% of women may experience VVC 
during their lifetime 
3
. Epidemiological and microbiological studies indicate that intrauterine infection 
accompanies 25 to 40% of preterm births 
4
.  The role of Candida colonization was confirmed in the 
occurrence of preterm birth
5
, as the Candida were isolated from amniotic fluid in women with spontaneous 
preterm birth
5,6
.  Candida has been found to increase metalloproteinase 9 production by chorioamniotic 
membranes
6
. Metalloproteinase 9 is a protein that remodels connective tissue and has an important role in 
the origin of premature labor and early rupture of membranes
7
.  Also, the mother's vulvovaginal candidiasis 
is a major risk factor for neonatal Candida colonization
8
. There is evidence that eliminating Candida species 
during pregnancy may reduce the risk of spontaneous premature birth 
9
. 
   In epidemiology, vulvovaginal candidiasis (VVC) is the second most common cause of vaginosis 
worldwide, after a bacterial infection. The risk of VVC for non-pregnant women is about 20%, but it 
increases by 30% during pregnancy
10
. Usually (90%) of infections due to Candida albicans are harmless and 
do not cause any symptoms. However, vaginal or vulvar infection may be associated with symptoms and 
signs such as severe itching, pruritis, pain, irritation, bad odor, dyspareunia, and dysuria and burning in 
urination
10
.  In the Arabian Peninsula, the epidemic of VVC infection varies in different countries, even from 
regions within the same country 
11-13
. Thus, local studies are important to obtain relevant epidemiological 
data and features of Candida sensitivity to antifungal drugs in order to help manage and treat patients with 
Candida infection. 
   Regarding the causative species of VVC, some researchers report an increased prevalence of no-Candida 
albicans species, especially C. glabrata, C. krusei, and C. parapsilosis 
14
. Some researchers have also found 
that the incidence of C. albicans infection decreases and other Candida types including C. glabrata. C 
tropicalis, C. parapsilosis, C. kefyr, C. africana, C. dubliniensis, C. famata, C. guilliermondii and C. 
 
lusitaniae associated mainly with vulvovaginitis from patients with immunodeficiency or in pregnant 
women
10 
.  
   In Yemen, vaginitis is one of the most common conditions for seeking medical care. In the city of Sana’a, 
vaginal infections have spread in Yemen among 37.6% of women of childbearing age, with VVC associated 
significantly with less than 25 years of age and use of intrauterine contraceptives
15
, also in Hadramaut three 
hundred and seventy two (39.2%) of the 950 pregnant women suffered from abnormal vaginal discharge and 
were positive for bacterial vaginosis
16
. 
   Pregnant women are more likely to have vaginal colonization and yeast infections. The role of Candida 
colonization in the occurrence of preterm birth is well established. Knowing local epidemiology and 
identifying risk factors for preterm birth are important for prevention and management strategies, so the 
purpose of the current study was to determine the prevalence of Candida species in the vaginal swabs of 
pregnant women and to identify the risk factors associated with VVC. 
SUBJECTS AND LABORATORY METHODS 
   Pregnant women attending routine antenatal visits in Al-Olify –family Center in Sana'a city  were enrolled 
into a cross-sectional study carried out from June  2018  to March 2019. Inclusion criteria for subject 
selection were healthy individuals with no systemic disease. In addition, pregnant women who currently 
taking antifungal, steroids, antibiotics, or immunosuppressive drugs in the past 6 months were excluded. The 
sample included 190 pregnant mothers. All pregnant women was examined clinically by specialist and 
vaginal swabs were taken. The vaginal swabs were sent to the National Center of Public Laboratories 
(NCPHL) where the laboratory works were carried out.  Vaginal swabs samples were taken from 
participants after obtaining oral consent. The swabs were inoculated into Sabouraud's glucose agar 
supplemented with chloramphenicol and incubated at 37 °C for 24 to 48 hours under aerobic conditions in 
order to perform fungal culture. The identification of the Candida species was done by culture on 
HiCrome Candida Differential Agar at 35 °C for 48 h for production of species-specific colors. Data of 
demographic, clinical and risk factors were collected in a pre-designed questionnaire. 
DATA ANALYSIS 
The data was statistically analyzed using EPI-Info version 6. The difference in the distribution of Candida 
types among groups was based on a comparison of repeat distributions by chi-square test. The odds ratio 
associated with VVC risk factors was performed by 2x2 tables to obtain an OR, 95% CI, Chi squared and p 
value by uncorrected static tests where the value of p <0.05 was considered significant. 
ETHICAL APPROVAL 
We obtained written consent in all cases. Approval was obtained from the participants prior to collection of 
samples. The study proposal was evaluated and approved by the Ethics Committee, Faculty of Medicine and 
Health Sciences, University of Sana’a. 
RESULTS 
 A total of 190 pregnant women are included. The prevalence of vulvovaginal candidiasis (VVC) was 
51.6%. C. albicans accounted for 39.5% and non-Candida albicans accounted for 12.1% of isolates, mainly 
C. glabrata (4.7%), C. lipolytica (3.2%), and C. famata (2.1%). When VVC risk factors were considered, 
there were significant risk factors with the age group 20-24 years (61%, OR = 1.8), first trimester of 
pregnancy (61.1%, OR = 1.7), Multipara of  parity (61.8%, OR = 1.9), low socioeconomic level (60.4%, OR 
= 2.4), and illiteracy (68%, OR = 2.2). When clinical symptoms were considered, only 86.2% of affected 
females had clinical signs of VVC. Subgroup prevalence of vulvovaginal candidiasis is presented in Table 2. 
Younger women, <20 years had a somewhat lower prevalence (33.3%) of vulvovaginal candidiasis, while in 
the 20-24  years and older group, the prevalence was between 41.3%  and 71.4%. The adjusted odds ratio 
showed that vulvovvaginitis was not significantly associated with older age (p = 0.12). The prevalence of 
vulvovaginal candidiasis varied with gestational trimester, parity, education and sociodemographic level. 
Women who are illiterate were more affected than those patients with primary school education and above. 
Similarly, vulvovaginal candidiasis was higher among  low level of sociodemographic. Also  vulvovaginal 
candidiasis was higher among multipara mothers  (61.8%) compared to nulliparous (38.5%) or paucipares  
(54.4%) study subjects (Table 2). Table 4  shows  the prevalence of Candida species according to presence 
of symptoms. The Candida was isolated in most pregnant women who had symptoms of Candida VV 
(86.2%), while only 22.3% was isolated in pregnant women who had no symptoms of  Candida VV. There 
was a higher rate of isolated albicans Candida in women with symptoms (73.6%) compared to 10.7% in 
women without symptoms. On the other hand, the percentage of non-Candida albicans in symptomatic 
women (11.7%) is almost similar to 12.6% in asymptomatic women. 
DISCUSSION 
Information on the prevalence of vulvovaginal candidiasis in Yemen is not known. Unfortunately, 
vulvovaginal candidiasis is not a reportable disease and diseases are routinely diagnosed by sign and 
symptoms without supporting laboratory diagnosis. As a result, the spectrum of yeasts involved in causing 
 
the disease is unknown in Yemen. The prevalence of vulvovaginal candidiasis among pregnant women is 
also unknown in Yemen, but it is known worldwide that it is the second most common infection in the 
vaginal vulva area in women with symptoms as it represents about 17% to 42.%
17-19
.  
   Even though the prevalence of infection in the current study (51.6%) was slightly higher than the reported  
range, 
17-19
, it was higher than the prevalence rates reported by Ahmed and others in India among pregnant 
and non-pregnant women 
18
 and Olowe et al. in Nigaria among pregnant women 
19
, however lower 
prevalence was reported by ERylander et al. among sexually active young women and association with 
orogenital sex
20
.  Differences in rates can be explained by identifying differences in the sociodemographic 
characteristics and immunity status of patients 
21
, treatment of patients with extensive antibiotics, 
immunosuppressive drugs
22
 and hormonal effects
23
 as some of the factors for differences in prevalence and / 
or recurrent  vulvovaginal candidiasis between studies. 
   Age, level of education, pregnancy stages, parity and socio-demographic status were investigated as 
potential risk factors for vulvovaginitis in the present study.  There was no strong evidence for the 
association between level of education, gestational trimester, and prevalence of vulvovaginal candidiasis. 
Among the sociodemographic characteristics, age appears to be an important factor in the occurrence of 
vulvovaginal candidiasis in general as the rate of vulvovaginal candidiasis was 61% with OR = 1.8, 95% CI 
= 1-3.9, P = 0.04 in the 20- 24 years age group (Table 2). The current result was similar with a previous 
study by Sobel et al.
24
, they indicated that vulvovaginal candidiasis is rare in puberty (the first occurrence of 
menstruation), but its frequency increases with the end of the second decade of life (10-19 years) and 
reaches its peak in the third (20-29 years) and the fourth decade (30-39 years old). 
   Although in the current study, the odds ratio detected for the 20-24 age group was significant;  the 
association of older age groups and vaginal candidiasis was not statistically significant as far as the adjusted 
odds ratio was considered (Table 2); this may point toward that the association was affected by other 
variables. The incidence was more in pregnant women who are illiterate (68%) than in patients with 
university education (39.7%). The improvement in personal hygiene and / or the economic situation 
resulting from education may explain the difference in the incidence rate among the illiterate and the people 
who got better education. Our results were consistent with those of Rathod et al. in India 
25
, but in 
disagreement to the conclusion of Vadav and Prakash
26
. 
Among the six Candida species isolated in this study, the recovery rate for C. albicans was 39.5% , 9 (4.7%) 
for C.globrata, 2 (1.1%) for  C.dubliniensis, 1 (0.52%) for  C.rugosa, 6 (3.2%) for C.lipolytica and for  
C.famata 4 (2.1%) (Table 3).  The results of the current study of C. albicans as the predominant species were 
reliable with similar previous studies
24, 27
. Although many studies on the prevalence of different types of 
Candida have led to the general concurrence that C. albicans are the most common isolated species in 
patients with vulvovaginal candidiasis, there has been an increasing trend to recover non-albicans Candida 
species. This is evidenced by the current study in which the isolation rate of non-albicans Candida species 
was 12.1%. By comparison, more recovery rates for non-albicans Candida species were reported at 41.4% 
in India
28
 31.7% in Belgium
29
 and 19.8% in the United States 
27
. Also more higher recovery rates of 53.1%, 
65.0% and 57.5% of non-albicans Candida species have been reported in studies conducted in India 
18
, 
Egypt 
30 
 and Iran
31
, respectively. 
   Differences in the cure rate were observed between types of non-albicans Candida species between the 
current study and many previous studies. The recovery rate is 4.7% for C.globrata, 1.1% for C. dubliniensis, 
0.52% for C.rugosa and 3.2% for C.lipolytica and C.famata 2.1% similar to what Trama et al. 
27
. Studies of 
Sobel et al. 
24
, Nergessie 
32
, Sobel et al. 
33
, they were revealed that C. glabrata was the predominant yeast 
among non-albicans Candida species. Bauters et al. research 
29
 showed that C. glabrata was the most 
common non-albicans Candida species (16.3%), followed by C. parapsilosis (8.9%), C. humicola (1.6%), 
C. krusei (0.8%), and C. lusitaniae (0.8 %). Hassanvand et al. 
34
 C. albicans proved to be the most common 
isolated species followed by C. glabrata, C. tropicalis, and C. parapsilosis. The significance of this result 
can be explained with caution that C.globrata may replace C. albicans under selective pressure of 
fluconazole, leading to inflammatory resistance to current fluconazole-based treatment in Yemen. 
 
CONCLUSIONS 
   There is a high rate of VVC among pregnant women in Yemen, and this highlights the need for health 
authorities to develop strategies to diagnose VVC, including vaginal swabs for candidiasis as a routine 
procedure for all pregnant women. This study also revealed a steady increase in time with a non-
C. albicans species  prevalence rate. The guidelines for managing VVC syndrome in Yemen should be 
revised to include a special protocol for pregnant women. 
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Table 1:  The distribution of  pregnant  women according to their age   
  
Case n =190 pregnant women 
Age groups 
% NO. 
9.5 18 < 20 years 
37.9 72 20 -24 years 
30.5 58 25-29 years 
14.7 28 30-34 years 
7.4 14 ≥ 35 
25.4 years Mean age 
4.9  years S. D 
25 years Mode 
25 years Median 
39 years Max 
17 years Min 
95 % Total 
 
Table 2: The risk factors of  VV Candidiasis  among pregnant women in Sana'a city 
 
 characters 
Positive VVC 
n=98 OR CI X² P 
No % 
Age group 
< 20 years n=18 8 33.3 0.7 0.27-1.9 0.4 0.52 
20-24years n=72 44 61 1.8 1.0-3.4 4.2 0.04 
25-29 years n=58  24 41.3 0.5 0.29-1.0 3.5 0.06 
30-34 years n=28 12 42.8 0.66 0.2-1.4 1.0 0.3 
> 35 years n=14 10 71.4 2.5 0.7-8 2.3 0.12 
Gestational  trimester n=190 
First n= 54 33 61.1 1.7 0.9-3.2 2.7 0.09 
Second n=78 36 46.2 0.7 0.3-1.2 1.5 0.21 
Third n=58 29 50 0.91 0.4-1.6 0.08 0.77 
Parity 
Nulliparous (0 birth)  n=65 25 38.5 0.4 0.21-0.8 6.8 0.009 
Paucipares  (1-2 birth) n=57 31 54.4 1.2 0.6-2.1 0.25 0.6 
Multipara (>2 birth) n= 68 42 61.8 1.9 1.03-3.5 4.4 0.03 
Sociodemographic 
Low n= 111 67 60.4 2..4 1.3 -4.2 8.2 0.004 
Intermediate n=79 31 34.4 0.4 0.2-0.76 8.2 0.004 
Educational status 
Illiterate n=25 17 68 2.2 1-5.3 3.1 0.07 
Primary school n=32 19 59.4 1.5 0.9-3.1 0.9 0.33 
Secondary school n=65 35 53.8 1.1 0.6-8 0.2 0.65 
University n=68 27 39.7 0.47 0.25-0.8 5.9 0.01 
VVC clinical signs 
Yes n=87 75 86.2 21.7 10-46 77 <0.0001 
No n= 103 23 22.3 0.04 0.02-0.09 77 <0.0001 
OR=Odds ratio, CI= confidence interval, Χ2 =Chi square, p= p value. 
 
 
 
Table 3: The frequency of  different species of Candida isolated  from pregnant women  
 
Micro-organism species 
Pregnant women  
No. % 
Candida spp 98 51.6 
Candida albicans 75 39.5 
Non-candida albicans spp 23 12.1 
C.globrata 9 4.7 
C.dubliniensis 2 1.1 
C.rugosa 1 0.52 
C.lipolytica 6 3.2 
C.famata 4 2.1 
 
 
 
Table 4: The prevalence of Candida species according to presence of symptoms 
 
 
Micro-organism 
species 
Asymptomatic  n=103 Symptomatic n=87 
No. % No % 
Candida spp 23 22.3 75 86.2 
C.albicans 11 10.7 64 73.6 
Non-candida 
albicans 
12 11.7 
11 12.6 
C.globrata 6 5.8 3 3.4 
C.dubliniensis 2 1.9 0 0 
C.rugosa 1 0.97 0 0 
C.lipolytica 1 0.97 5 5.7 
C.famata 2 1.9 2 2.3 
Total 23 22.3 75 86.2 
  
 
 
 
